Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study).

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511397-70-00

Acronym

AxIn

Enrollment

178

Registered

2024-03-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic renal cell carcinoma (mRCC)

Brief summary

• To evaluate the overall response rate in patients treated with the axitinib in addiction to SOC compared to SOC alone.

Detailed description

• To evaluate the efficacy of axitinib in addiction to SOC compared to SOC alone in terms of: a) Progression free survival b) Overall survival c) Depth of response d) Duration of response e) Quality of life • To evaluate the safety of axitinib in addiction to SOC compared to SOC alone

Interventions

DRUGAXITINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• To evaluate the overall response rate in patients treated with the axitinib in addiction to SOC compared to SOC alone.	—

Secondary

Measure	Time frame
• To evaluate the efficacy of axitinib in addiction to SOC compared to SOC alone in terms of: a) Progression free survival b) Overall survival c) Depth of response d) Duration of response e) Quality of life • To evaluate the safety of axitinib in addiction to SOC compared to SOC alone	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026